Unresectable Melanoma
📧 Sign up to get email alerts when something new happens for Unresectable Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]
Phase 2 trial evaluating rigosertib in combination with pembrolizumab for unresectable or metastatic melanoma that is refractory to PD-1 inh…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma [Phase 3]
A Phase III randomized trial comparing the PD-1 inhibitor JS001 (toripalimab) to dacarbazine as first-line therapy for unresectable or metas…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations [Phase 1]
Phase 1 bioequivalence study comparing Binimetinib 3 x 15 mg formulation with a 45 mg formulation in melanoma patients with BRAF V600 mutati…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma [Phase 2]
Phase 2 trial evaluating lifileucel with reduced-dose fludarabine/cyclophosphamide lymphodepletion and interleukin-2 for unresectable or met…
-
CLINICAL_TRIALS trial_result · 2023-12-22Clinical Trial Update: A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma [Phase 2]
Phase 2 study evaluating sotigalimab (APX005M) in unresectable or metastatic melanoma has been terminated with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-01Clinical Trial Update: Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma [Phase 2]
A Phase 2 study compares the combination of ipilimumab and nivolumab versus ipilimumab alone in advanced melanoma, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) [Phase 2]
Phase 2 clinical trial update for INCMGA00012 in selected solid tumors, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC [Phase 1, Phase 2]
Phase Ib/II trial evaluating fecal microbiota transplant in combination with nivolumab for metastatic or inoperable melanoma and NSCLC; stat…
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer [Phase 1, Phase 2]
Phase 1/2 trial update of uprosertib combined with dabrafenib and trametinib in patients with stage IIIC-IV melanoma (cutaneous/metastatic/u…
-
CLINICAL_TRIALS trial_result · 2020-09-07Clinical Trial Update: LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [Phase 2]
Phase II open-label trial evaluating dabrafenib plus trametinib in unresectable stage III/IV BRAF-mutant melanoma; study completed with post…
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery [Phase 2]
Phase 2 trial evaluating nab-paclitaxel with bevacizumab or ipilimumab as first-line therapy in patients with unresectable stage IV melanoma…
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) [Phase 3]
Phase 3 trial comparing BMS-936558 (nivolumab) to physician's choice chemotherapy in advanced melanoma after anti-CTLA-4 therapy; trial comp…
-
CLINICAL_TRIALS trial_result · 2016-03-16Clinical Trial Update: An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma [Phase 2]
Phase 2 open-label trial of lenvatinib in previously treated patients with unresectable stage III or stage IV melanoma completed; results po…